SACI-IO HR : A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
1. 请及时下载文件确认是否正确, 系统将在 2026-06-30 13:51:58 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.annonc.2026.06.012
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0923753426009609
其他信息:
出版社: Elsevier BV
作者: A.C. Garrido-Castro; S.E. Kim; T. Li; J. Desrosiers; R. Nanda; Y. Abdou; A.S. Clark; R.L. Sacks; T. O’Connor; N. Sinclair; S. Lo; G. Augdahl; E. Wrabel; M. DiLullo; T. Rahman; A. Patel; M.E. Hughes; J. Baginska; P.B. Lange; T. O’Meara; T.E. Keenan; A. Gorthi; A. D’Ippolito; C.A. Painter; M. Eaton; J.C. Barrett; B. Koca; P.T. Kurnia; A.N. Perry; J. Gomez Tejeda Zanudo; M. He; D.A. Dillon; N.U. Lin; H.J. Burstein; E.A. Mittendorf; R. Jeselsohn; D.L. Rimm; N. Tayob; S.M. Tolaney
